Was Aptensio XR discontinued?
Aptensio XR (an extended-release methylphenidate) was discontinued by the manufacturer according to information published by FDA’s Orange Book and related product listings, which show the product as no longer marketed [1].
When did it stop being sold?
The Orange Book status reflects marketing changes rather than a single “stop date.” Users typically see discontinuation through the product no longer appearing as an available reference product, alongside subsequent changes to availability windows at pharmacies and wholesalers [1].
What should patients do if Aptensio XR was discontinued?
If Aptensio XR is no longer available, clinicians commonly switch patients to another extended-release methylphenidate product (or an alternative ADHD medication class) based on symptom control, side-effect history, and dosing history. The exact substitution depends on what strength and dosing schedule the patient used before.
What are common alternatives to Aptensio XR?
Patients are often transitioned to other FDA-approved methylphenidate extended-release formulations, which differ by bead/coat technology and dosing instructions. Clinicians choose an alternative that best matches the prior daily exposure and tolerability profile [1].
Could there be supply issues even before a formal discontinuation?
Yes. Even when a product remains listed in some systems, pharmacies can experience intermittent shortages or limited manufacturer distribution. That can prompt earlier switching before the product is fully reflected as discontinued in national listings [1].
Are there lawsuits or recalls tied to the discontinuation?
The provided source for discontinuation is the FDA Orange Book listing status [1]. The Orange Book entry does not, by itself, establish a recall or legal cause for discontinuation, so any lawsuit/recall connection would need to be checked separately in FDA safety communications and court/industry reporting.
Sources
[1] https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm